The market for ‘gene silencing’ therapies is set to explodeDr Dan WilliamsDec 16, 20241 min readDan Williams discusses the reasons behind the gene silencing explosion in FirstWord Pharma. Read his analysis here.
Drug Target Review features an insightful article by Dan Williams that explores the extraordinary achievements of AI in drug design
Technology Networks features a major interview with Dr Uwe Meya, SynaptixBio’s CMO, in which the issues around organising, funding, and conducting clinical trials for rare diseases are discussed.
Dan Williams contributes to a major article for Inside Precision Medicine, in which several US families with a child living with H-ABC discuss their journey to a diagnosis
